Loading stock data…
PAVM
$4.68-0.50 (-9.65%)
After Hours$4.76+0.08 (+1.71%)· Last close Jun 9
PAVmed Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PAVmed Inc. in the Healthcare sector is trading at $4.68. Wall Street consensus targets $36.00 (2 analysts), implying a +669.2% move over the next 12 months. The stock is currently near its 52-week low of $4.68, remaining 54.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +669.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 17) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.68
Potential Downside
0%
Whystock Fair Value$4.68
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$36.00+669.2%
Range$16.00 – $56.00
Fundamentals
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for u...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.13%
Volume
Today's trading volume
37,628
Recent News
How The PAVmed (PAVM) Narrative Is Shifting With Reworked Assumptions And A Lower Price Target
PAVmed’s latest analyst update keeps fair value unchanged at US$40.50 but comes alongside a US$44 cut to the price target that has drawn fresh attention. Analysts frame this move as a recalibration tied to updated assumptions rather than a reaction to a single headline, which affects how the signal may be interpreted. Looking ahead, these shifting targets can be viewed within a broader narrative that investors may track over time. Stay updated as the Fair Value for PAVmed shifts by adding it...
PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ...
PAVmed Inc (PAVM) navigates a transformative quarter with capital restructuring and promising subsidiary developments, despite facing financial hurdles and increased operating expenses.
PAVmed (PAVM) Q4 2025 Earnings Transcript
Lishan Aklog: Thank you, Matt, and good morning, everyone. On our last quarterly call, I described how over the past now 2 years, we've undertaken a series of very deliberate and systematic actions to effectively permanently fix PAVmed's legacy capital structure and ultimately strengthen its balance sheet and improve our ability to execute on our strategic plan.
PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates
PAVmed (PAVM) delivered earnings and revenue surprises of -69.57% and -78.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -40.00% and -10.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?